Evercore ISI raised the firm’s price target on Vertex Pharmaceuticals to $379 from $375 and keeps an Outperform rating on the shares. VX-880, Vertex’s off-the-shelf T1D cell therapy, continues to deliver “impressive” efficacy in more patients with longer follow-up and new data gives the firm comfort to increase its view of the odds of success for VX-880 to 40% from 20%, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VRTX:
- Vertex Pharmaceuticals and Lonza to build facility for T1D cell therapies
- Vertex Pharmaceuticals reports ‘positive’ Phase 1/2 VX-880 results
- Vertex announces FDA approval for KALYDECO to treat eligible infants with CF
- Vertex Pharmaceuticals price target raised to $400 from $325 at Maxim
- Vertex Pharmaceuticals price target raised to $363 from $344 at Bernstein